Bavarian Nordic nets large mpox vaccine supply pact, boosts revenue outlook after string of deals
In the latest of several recent mpox vaccine supply deals, Bavarian Nordic plans to provide 1 million doses of its shot, Jynneos, to affected African countries through an agreement with UNICEF. | The agreement is the latest in a string of mpox vaccine supply deals that have come in response to the ongoing outbreak in Africa.
Bavarian Nordic signs agreement with UNICEF for one million mpox vaccines
Bavarian Nordic said on Thursday it has signed an agreement with the United Nations Children's Fund (UNICEF) for one million doses of its mpox vaccine, Jynneos, for countries in Africa impacted by the disease outbreak.
Bavarian Nordic gains US contract for additional mpox vaccine
The vaccine bulk manufacturing is scheduled for 2025 with the delivery of the freeze-dried doses set for 2026.
Bavarian Raises Guidance After Securing More Mpox Vaccine Orders
Bavarian Nordic A/S, one of a few companies with an approved mpox vaccine, is upgrading its financial guidance after securing more orders for its jab as an outbreak rages in Africa.
Bavarian Nordic gets $63 million US government order for small pox, mpox vaccine
Bavarian Nordic has received an order worth $63 million from the U.S. government to produce additional bulk product and the final freeze-dried doses of its mpox and smallpox vaccine, Jynneos, it said on Tuesday.
Bavarian Nordic Secures $63M Order for Jynneos Mpox Vaccine
Bavarian Nordic has received a $63 million order from BARDA to produce Jynneos mpox vaccine doses. The contract will support the manufacturing of 1 million freeze-dried vaccines, set for delivery by 2026,
Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines
Contract will further strengthen the U.S, bulk vaccine inventory and secure additional freeze-dried dosesDeliveries planned for 2025 and beyond COPENHAGEN, Denmark, September 24, 2024 – (OMX: BAVA) today announced that it has received an additional order valued at USD 63 million from the Biomedical Advanced Research and Development Authority (BARDA),
Bavarian Nordic Updates FY24 Outlook
(RTTNews) - Bavarian Nordic A/S (BVNRY.PK), Thursday announced an updated guidance for the fiscal year 2024, primarily due to the bulk Mpox vaccine orders secured by the company as well as improved ...
Bavarian Nordic Upgrades its Financial Guidance for 2024
(OMX: BAVA) upgrades its financial guidance for 2024. Based on today’s announced mpox vaccine order and additional orders ...
devdiscourse3d
Bavarian Nordic Secures $63 Million U.S. Government Contract for Vaccine Production
Bavarian Nordic has secured a $63 million contract from the U.S. government to produce the Jynneos vaccine for mpox and ...
Nasdaq4d
Are Investors Undervaluing Bavarian Nordic (BVNRY) Right Now?
One company value investors might notice is Bavarian Nordic (BVNRY). BVNRY is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. Another valuation metric that we should highlight is ...
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
First award under UNICEF emergency tender to secure availability of mpox vaccines for Africa COPENHAGEN, Denmark, September ...
Twin studies show Bavarian Nordic’s Mpox vax efficacy wanes in 1 year
Amid the rising global outbreak of Mpox, two separate studies have shown that the efficacy of Bavarian Nordic’s vaccine ...
Mpox in Africa: Vaccine efforts ramp up
An alarming surge in mpox cases has hit Africa, with more than 32,000 suspected infections recorded. The continent faces a ...